Home / Stocks / ASND

Ascendis Pharma A/S (ASND, Biotechnology) Stock Valuation & Fair Value No P/E valuation

Ascendis Pharma A/S (ASND, Biotechnology) trades at a blended P/E of 22.1, trading without a historical P/E to compare against, with a forward growth estimate of 20.5% and a PEG of 1.08. Analysts' one-year estimates have been hit 30% of the time.

This company has no P/E to compare against its own history, so tickerseer publishes no valuation rating for it. The figures below are unaffected.

DATA AS OF 2026-09-21
Blended P/E
22.1
Normal P/E
—
PEG
1.08
Fwd growth
20.5%
Div yield
0.0%
RSI (14)
37.6
Neutral

The Street vs SeerForecast

Wall Street's mean price target for ASND is $311.29 across 20 analysts, 39.5% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: we publish none, because it has no P/E to compare against its own history. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer has published no valuation rating since 2026-07-31, because this company has no P/E to compare against its own history.

Blended P/E and rating by weekBlended P/E moved from 33.7 to 22.1 between 2026-07-31 and 2026-09-21, with 2 rating changes over 18 recorded weeks.2026-07-31: P/E 33.7, No P/E valuation (recalculated)2026-08-03: P/E 32.5, No P/E valuation2026-08-07: P/E 32.5, No P/E valuation (recalculated)2026-08-10: P/E 32.3, No P/E valuation2026-08-14: P/E 32.3, No P/E valuation (recalculated)2026-08-17: P/E 33.7, No P/E valuation2026-08-21: P/E 33.7, No P/E valuation (recalculated)2026-08-24: P/E 27.6, No P/E valuation2026-08-27: P/E 27.6, No P/E valuation (recalculated)2026-08-28: P/E 27.6, No P/E valuation (recalculated)2026-08-30: P/E 27.6, No P/E valuation (recalculated)2026-08-31: P/E 25.9, No P/E valuation2026-09-05: P/E 25.9, No P/E valuation (recalculated)2026-09-07: P/E 27.1, No P/E valuation2026-09-12: P/E 27.1, No P/E valuation (recalculated)2026-09-14: P/E 25.4, No P/E valuation2026-09-19: P/E 25.4, No P/E valuation (recalculated)2026-09-21: P/E 22.1, No P/E valuation25.030.0Jul 31Aug 13Aug 26Sep 8Sep 21
Attractively valuedNo P/E valuationAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 33.7not availableNo P/E valuation
2026-09-21P/E 22.1not availableNo P/E valuation ← now

Frequently asked questions

Is Ascendis Pharma A/S stock overvalued?

At a blended P/E of 22.1, Ascendis Pharma A/S has no historical normal P/E on record to compare that against, with a PEG of 1.08 on 20.5% forward growth. tickerseer therefore publishes no valuation rating for it.

What is Ascendis Pharma A/S's fair value and PEG?

Ascendis Pharma A/S trades at a blended P/E of 22.1, a PEG of 1.08, and a forward growth estimate of 20.5%.

Has tickerseer's rating of Ascendis Pharma A/S changed?

tickerseer has published no valuation rating since 2026-07-31, because this company has no P/E to compare against its own history.

What is the analyst price target for Ascendis Pharma A/S?

The mean Wall Street price target for Ascendis Pharma A/S is $311.29 across 20 analysts, 39.5% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ASND free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.